NEWPORT NEWS, Va. — September 10, 2025 — ivWatch, LLC, the IV safety company, today announced its schedule of fall conference exhibitions and speaking engagements, including the Association for Vascular Access Annual Scientific Meeting in Kissimmee, Florida, the ANCC Magnet & Pathway Conference in Atlanta, Georgia, and the Global Health Exhibition in Riyadh, Saudi Arabia. In addition, ivWatch is hosting a webinar featuring neonatal vascular access expert Roland (Matheus) van Rens, who will discuss how early detection, combined with the 7 Rights framework for vascular access, can improve patient outcomes in the NICU.
Details of these upcoming events include:
Association for Vascular Access Annual Scientific Meeting, Kissimmee, Florida | September 19-21
ivWatch will be showcasing its IV monitoring technology at booth #607. To book a meeting, sign up here. Don’t miss ivWatch’s Chief Technology Officer, Jason Naramore’s presentation on September 20 at 3:30 pm: “How Lipid-based Drug Extravasations are Different from Other Drug Extravasations.” This presentation will uncover why lipid-based infusions behave differently, the risks they pose, and how technology can detect and prevent serious injury.
ANCC Magnet & Pathway Conference, Atlanta, Georgia | October 8-10
Discover ivWatch’s IV monitoring technology at booth #1831, where clinicians can see how continuous monitoring transforms IV safety in real-world practice. Attendees can experience firsthand how continuous monitoring helps clinicians detect infiltrations early, reduce injury severity, and elevate patient safety standards. With its focus on prevention, innovation, and measurable outcomes, ivWatch technology supports the patient safety goals that Magnet hospitals and leading healthcare systems strive to advance from a clinical, economic, and quality perspective. To book a meeting, visit here.
LIVE Webinar: “Addressing Risk with Early Recognition: Reducing the Severity of IV Harm”
October 16 | 12:00 pm ET
Neonatal vascular access expert Roland (Matheus) van Rens will share clinical evidence from three neonatal studies – including a recently published retrospective cohort study of 32,000+ IV insertions analyzed – and discuss how early detection, combined with the 7 Rights framework for vascular access, can improve outcomes in the NICU. Topics include:
- The prevalence and clinical impact of PIVIEs
- Applying the 7 Rights to improve vascular access outcomes
- Pitfalls and limitations of routine observation techniques
- Evidence that sensor-based monitoring reduces PIVIE severity and supports safer practice
To register for the webinar, visit here.
Global Health Exhibition, Saudi Arabia | October 27-30
ivWatch will be exhibiting alongside Al Madar Medical booth # H3.E10 at the Global Health Exhibition in Riyadh, showcasing its continuous IV monitoring technology that enables early detection of infiltrations and reduces patient harm. As Saudi Arabia advances its Vision 2030 healthcare goals, ivWatch is proud to support hospitals in raising standards of infusion safety. Together with Al Madar Medical, the team looks forward to engaging with healthcare leaders and partners to expand access to this innovation across the region.
To learn more about the ivWatch patient monitoring system for IV infiltrations and extravasations, visit: https://www.ivwatch.com/tech-overview/.
About ivWatch
IV insertion is the most common hospital procedure, yet up to 50% of them fail, often with severe consequences ranging from dosing errors, scarring, skin staining, nerve damage, amputation, and even death. Newport News, Virginia-based ivWatch is changing that.
Founded in 2010 and holding nearly 70 patents and counting, the company has developed a first-of-its-kind Class II medical device, cleared by the FDA and CE-marked, that uses visible and near-infrared light and a predictive algorithm to continuously monitor peripheral IVs to aid in the early detection of IV leakage events, also known as infiltration and extravasation.
Applied to the skin at the IV site, ivWatch sensors perform over 18,000 checks per hour for signs of IV infiltration and extravasation, notifying healthcare workers of fluid leakage outside of the vein in real time to reduce severe adverse outcomes.
In 2024, the company surpassed more than 35 clinical bodies of evidence. It was also named to Fast Company’s Most Innovative Companies list, the Inc. 2024 Best in Business list in the Health Products category, and was recognized by Modern Healthcare as one of its 2024 Best in Business. The company also reached the Top 3 in the 2024 Startup World Cup Grand Finale, from an initial group of over 8,000 global startups. To learn more, visit www.ivwatch.com.